Back to results
US 2025/0329431 A1Published application
Method of predicting non-small cell lung cancer (nsclc) patient drugresponse or time until death or cancer progression from circulating tumordna (ctdna) utilizing signals from both baseline ctdna level and longitudinalchange of ctdna level over time
AssigneeGuardant Health, Inc.
InventorsBojan LOSIC, Katie Julia QUINN, Sean Gordon
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of determining a molecular response score for use in predictive models. The molecular response score may be used to monitor and guide administration of treatment to a subject.
Claims25
A method, comprising:
- receiving, by a computer system, genetic information of a subject comprising data taken at two or more time points and wherein cancer is detected in the subject;
- extracting one or more features from the genetic information, the one or more features identified from a plurality of samples obtained from the subject;
- generating, by a first classifier implemented by the computer system using a first machine learning algorithm, a first output indicating a first classification of the subject;
- generating, by a second classifier implemented by the computer system using a second machine learning algorithm, a second output indicating a second classification of the subject;
- identifying, by the computer system and from a population, additional subjects with genetic information that match the subject's genetic information based on the first classification and the second classification;
- determining, by the computer system, at least one score with respect to the subject based additional subjects with matching genetic information;
- determining, by the computer system, a composite score using the at least one score;
- and
- determining, by a recommender implemented by the computer system, a recommendation indicating a treatment for the subject based on the composite score.
6 more elements
-26. (canceled)
Dependencies are inferred from the claim text.